Catheter ablation for atrial fibrillation in patients with end-stage heart failure and eligibility for heart transplantation.
Christian SohnsNassir F MarroucheAngelika Costard-JäckleSamuel SossallaLeonard BergauRene SchrammUwe FuchsHazem OmranKerstin RubarthDaniel DumitrescuFrank KonietschkeVolker RudolphJan F GummertPhilipp SommerHenrik FoxPublished in: ESC heart failure (2020)
CASTLE-HTx will determine if AF ablation has beneficial effects on mortality in patients with end-stage HF who are eligible for HTx.
Keyphrases
- catheter ablation
- atrial fibrillation
- heart failure
- left atrial
- left atrial appendage
- oral anticoagulants
- acute heart failure
- direct oral anticoagulants
- cardiovascular events
- percutaneous coronary intervention
- risk factors
- left ventricular
- cardiovascular disease
- type diabetes
- cardiac resynchronization therapy
- mitral valve